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Results
1. 12 companies answered the survey. All of them knew the QbD concept in the context of the ICH quality guidelines.
Perception and Application of the 
Concept “Quality by Design” (QbD) by the Pharmaceutical 
Industry in Portugal
Garcia A.C.(1,2), Fernandes P.O.(3,4), Santos A.O.(1,2)
(1) CICS-UBI – Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal, (2) FCS - Faculty of Health Sciences, University of Beira Interior, 
Covilhã, Portugal; (3) Research Unit NECE, University of Beira Interior, Covilhã, Portugal, (4) Department of Economics and Management, School of 
Technology and Management (ESTiG) of Polytechnic Institute of Bragança (IPB), Bragança, Portugal
@ www.fcsaude.ubi.pt/cics
Introduction
Quality by Design (QbD) is an emerging driving force and multi-process
approach that is becoming a priority for both regulators and the
pharmaceutical industry. It is integrated in the entire chain of a product
lifecycle, since design, passing through development and ending only at
discontinuation of the product. It states that in order to ensure predefined
product quality, improve manufacturing quality performance and serve
customers’ needs, one must fully understand the processes behind it1,2.
The International Conference on Harmonisation (ICH) guidelines Q8, Q9 and
Q10, and more recently Q11, provide a solid foundation and guidance for
better understanding and applying this new paradigm.
Aim
To assess the Portuguese pharmaceutical companies’ perception about the usefulness of a strategy of development,
production optimization and control/quality management according to the QbD concept and its level of
implementation.
Methodology & Methods
Survey to 28 licensed entities listed by INFARMED for the production of drug substances and products (excluding
medicinal gases). Answers were collected between 16/12/2014 and 1/06/2014. It had 2 groups of questions: the first
one intended to characterize the industries and the second one to give answers to the study aim. SPSS (v.21) was
used for data analysis. Inferential analysis (association between variables) used Fisher's exact test.
Discussion & Conclusion 
 Portuguese industries are aware of regulatory proceedings and are
keeping pace towards global regulatory harmonisation. QbD has
importance among the industries having R&D activities (p-
value=0,024, assuming a significance level of 5%)*.
 In spite of industries ambition to succeed throughout this integrative
strategy, there is still the need to better learn the “know how” and
master the skills underlying QbD.
 To invest time and manpower might be essential to go beyond
theoretical knowledge and to acquire the tools and competences for
approaching more efficiently this concept.
Portuguese industries still  have a long path ahead of them towards full 
adoption of QbD and proving its benefits. 
We propose that the Portuguese academy should also participate, giving 
pharmacy students the awareness and competences in the use of QbD
tools and concepts.
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Might be done with straight cooperation of regulatory agencies (ICH, 
EMA, FDA) and experts of this field.
Acknowledgments
We would like to acknowledge the panel of experts that revised the survey:
Cláudia Silva, PharmD, PhD Head of Research Bluepharma (pharmaceutical
company); Bruno Gago, PharmD, PhD Invited Assistant Professor and Deputy
Director of the training programme in Pharmaceutical Medicine, University of
Aveiro; and Paula Correia, PharmD, Regulatory Affairs professional at
GlaxoSmithKline (pharmaceutical company).
8,1%
18,9%
27,0%
13,5%
13,5%
13,5%
5,4%
Process Analytical Technology
Design of Experiments
Quality risk assessment & management
Quality Target Product Profile
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Knowledge management
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4. QbD tools/aspects in use or in implementation
Response frequency (percentage)
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Development of analytical methods
Process improvement
Development of synthetic APIs
Development of non biological innovative
drugs
Development of generic drugs
Already marketed products under QbD
paradigm
5. Scope of use and implementation of QbD
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6. Industry sectors under QbD influence
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Uncertainties on how to actually implement the principles of QbD
Difficulty in quantifying both the benefits of QbD and investment return
Perception of increased time for reaching market
Inability/difficulty of allocating time and qualified staff
Other
8. Obstacles towards implementation  of QbD
Response frequency (percentage)
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17,9%
17,9%
32,1%
17,9%
14,3%
Greater flexibility / capacity to intervene in
the manufacturing process
Improvement of the quality in the final
product
Robustness in product quality & reduction
of the risks of "non-compliance" and costs
Shorter release time of of batches
Scale transposition and techology transfer
Response frequency (percentage)
7. Benefits indicated as possibly achieved 
through QbD
